Ascentage Pharma Announces 2022 Annual Results Including Strong Sales of Olverembatinib and Steady Progress in Transition Towards Biopharma
- Written by PR Newswire
![]() |
SUZHOU, China and ROCKVILLE, Md., March 23, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its annual results for the full year 2022. During the reporting period, the company upheld the...















